Point72 Asia Singapore Pte. Ltd. Has $77,000 Position in LivaNova PLC (NASDAQ:LIVN)

Point72 Asia Singapore Pte. Ltd. trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 58.2% during the second quarter, HoldingsChannel.com reports. The firm owned 1,402 shares of the company’s stock after selling 1,952 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in LivaNova were worth $77,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Hexagon Capital Partners LLC boosted its position in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares during the period. Fifth Third Bancorp grew its stake in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in LivaNova in the first quarter valued at $84,000. Canada Pension Plan Investment Board bought a new position in LivaNova during the 2nd quarter worth $88,000. Finally, Acadian Asset Management LLC bought a new stake in shares of LivaNova in the 1st quarter valued at about $94,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the stock. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday. They set a “buy” rating and a $65.00 price target on the stock. Stifel Nicolaus lifted their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Robert W. Baird upgraded shares of LivaNova from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $55.00 to $66.00 in a research note on Tuesday, September 17th. Finally, Needham & Company LLC raised their target price on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $69.83.

LivaNova Stock Up 1.2 %

Shares of NASDAQ LIVN opened at $53.83 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The company has a 50-day moving average price of $48.63 and a 200-day moving average price of $53.39. The stock has a market capitalization of $2.92 billion, a P/E ratio of -89.72 and a beta of 1.00. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. On average, equities research analysts forecast that LivaNova PLC will post 2.58 EPS for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.